High CDKN1B expression predicts sensitivity to hormone therapies and chemotherapy in luminal breast cancer patients, while its downregulation predicts resistance to radiotherapy and anti‐ERBB2 therapies.37 The gene discussed is CDKN1B; the disease is breast carcinoma.